����ӰԺ

Around a year after the company’s successful listing on the stock exchange, the Supervisory Board and Managing Board of Siemens Healthineers AG have drawn a positive conclusion. “The initial public offering of Siemens Healthineers on March 16, 2018, was extremely successful. It was the biggest IPO in Germany last year as well as the biggest in the medtech industry worldwide to date,” said Supervisory Board Chairman Michael Sen on Tuesday at the first Annual Shareholders’ Meeting of Siemens Healthineers AG, held at the Olympiahalle in Munich. Sen noted that the company is in an excellent position to benefit from the opportunities of a highly attractive market: “The crucial factors here are, first of all, greater entrepreneurial freedom, and second, more flexibility to set up a company that can focus exclusively on the special features of the healthcare market.”

Chief Executive Officer Bernd Montag talked about the industry’s fundamental developments and how Siemens Healthineers is profiting from them, thanks to its technology leadership: “Our innovations are shaping the healthcare of tomorrow. We help make diagnoses faster and more precise, and therapies more successful and easier on the patient.” He also discussed the company’s good performance in fiscal year 2018. “In the year of our IPO, we kept the promise we made,” Montag said.

Siemens Healthineers was listed on the stock exchange on March 16, 2018, at an issue price of EUR 28.00 per share. The move broadened the company’s entrepreneurial scope in a market that is undergoing a fundamental transformation, due in part to continuing cost pressure in the healthcare sector and technological progress in medical technology, for example through the use of artificial intelligence. Siemens Healthineers shares have risen more than 20 percent since they were first listed. Siemens AG remains the main shareholder with a stake of 85 percent.

For further information, please visit:
.

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.
In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.

This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as “expect”, “forecast”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “estimate”, “will”, “target” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens Healthineers’ management, of which many are beyond Siemens Healthineers’ control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. Should one or more of these risks, uncertainties or factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward looking statement. All forward-looking statements only speak as of the date when they were made and Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures that are or may be alternative performance measures (non-GAAP-measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers’ net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its Consolidated Financial Statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.